Table 2.

Univariate between-group differences in ThyPRO scale scores.

	Patient score, between-group difference
	Baseline			3 months			6 months			12 months
ThyPRO	Mean	s.d.	Pa	Mean	s.d.	Pa	Mean	s.d.	P a	Mean	s.d.	P a
Goitre symptoms
Malignant	21.4	18.5	0.93	25.5	21.5	0.71	21.5	21.5	0.80	15.7	17.7	0.84
Benign	21.7	16.2	ref.	27.3	21.2	ref.	20.3	20	ref.	14.9	17.4	ref.
Active surveillance	20.2	14.1	0.67	17.5	14.9	0.01b	17.0	12.0	0.34	19.2	14.9	0.25
Hyperthyroid symptoms
Malignant	13.3	16.3	0.33	16.1	19.0	0.67	17.5	19.8	0.61	16.4	16.9	0.21
Benign	16.8	18.0	ref.	17.8	18.0	ref.	19.8	21.2	ref.	21.4	21.1	ref.
Active surveillance	15.6	14.8	0.75	16.9	15.4	0.81	14.9	15.2	0.22	15.1	13.9	0.10
Hypothyroid symptoms
Malignant	20.6	23.4	0.72	21.7	25.6	0.74	24.1	25.4	0.96	22.2	23	0.75
Benign	22.5	25.0	ref.	19.9	23.3	ref.	24.4	26.2	ref.	23.9	26.1	ref.
Active surveillance	21.0	27.2	0.82	22.2	24.0	0.69	23.9	22.3	0.92	19.5	22.5	0.43
Eye symptoms
Malignant	10.8	18.5	0.84	16.3	21.3	0.62	15.5	19.7	0.75	11.5	14.8	0.34
Benign	11.5	17.4	ref.	14.0	18.9	ref.	14.1	16.5	ref.	14.8	17.3	ref.
Active surveillance	13.2	17.6	0.69	12.4	18.3	0.71	12.7	15.6	0.69	12.2	17.8	0.54
Tiredness
Malignant	29.6	24.1	0.35	32.9	23.9	0.12	33.7	23.6	0.59	32.4	23.4	0.47
Benign	34.5	23.1	ref.	41.2	25.0	ref.	36.5	25.5	ref.	36.1	23.3	ref.
Active surveillance	31.3	20.4	0.52	30.1	19.1	0.02	31.3	20.2	0.31	29.4	17.5	0.14
Cognitive impairment
Malignant	15.3	20.8	0.34	22.6	23.8	0.72	22.8	22.9	0.62	19.2	18.7	0.10
Benign	19.7	20.9	ref.	24.5	21.8	ref.	25.3	21.8	ref.	26.3	23.1	ref.
Active surveillance	16.6	20.0	0.52	16.4	20.0	0.09b	15.7	21.5	0.06b	16.8	20.0	0.05b
Anxiety
Malignant	23.2	21.1	0.15	25.3	23.8	0.36	22.1	22.7	0.31	16.0	18.5	0.05
Benign	29.8	20.1	ref.	30.1	24.3	ref.	27.2	25.1	ref.	24.7	23.4	ref.
Active surveillance	21.0	19.8	0.06	18.2	21.1	0.02b	18.8	18.3	0.08	19.5	22.4	0.33
Depressivity
Malignant	23.5	24.0	0.44	26.7	24.5	0.78	26.4	24.9	0.44	21.7	19.0	0.17
Benign	27.5	22.8	ref.	28.2	23.1	ref.	30.6	26.2	ref.	27.8	23.1	ref.
Active surveillance	21.9	19.7	0.25	16.3	15.8	0.005b	20.2	17.6	0.03b	20.1	17.8	0.09b
Emotional susceptibility
Malignant	23.8	23.2	0.25	28.1	22.7	0.42	26.6	23.5	0.27	23.0	20.5	0.08
Benign	29.5	19.5	ref.	32.2	22.7	ref.	32.3	24.4	ref.	31.3	23.3	ref.
Active surveillance	21.4	18.9	0.08	19.7	18.1	0.007b	20.7	14.9	0.005b	24.0	18.4	0.12
Social impairment
Malignant	9.8	16.5	0.99	14.6	19.7	0.68	16.1	24.1	0.55	10.6	18.9	0.65
Benign	9.8	16.8	ref.	12.8	18.7	ref.	19.3	26.2	ref.	12.5	22.8	ref.
Active surveillance	11.2	14.8	0.70	6.9	15.2	0.12	8.8	17.5	0.03b	7.3	13.0	0.16
Impaired daily life
Malignant	13.0	21.4	0.54	22.9	28.2	0.93	19.7	22.8	1	15.7	23.8	0.77
Benign	10.3	15.9	ref.	22.4	26.2	ref.	19.7	26.2	ref.	14.3	21.6	red
Active surveillance	9.1	16.6	0.76	7.0	12.6	<0.001b	8.1	15.2	0.007b	4.9	11.2	0.006b
Impaired sex life
Malignant	17.6	28.4	0.67	22.0	31.4	0.40	22	33.1	0.81	19.4	32.6	0.53
Benign	20.3	29.9	ref.	27.8	31.7	ref.	23.8	31.9	ref.	23.8	31.7	ref.
Active surveillance	23.8	34.1	0.66	17	28.7	0.12	19.2	29.8	0.53	16.7	31.6	0.35
Cosmetic complaints
Malignant	8.5	15.5	0.30	16.7	21.9	0.89	13.4	22.7	0.15	11.5	20.4	0.20
Benign	12.3	18.5	ref.	17.3	20.3	ref.	20.7	24.5	ref.	17.4	22.8	ref.
Active surveillance	13.7	15.7	0.73	7.7	11.6	0.004b	12.7	18.9	0.10	10.5	13.8	0.08
Negative influence on QoL
Malignant	23.5	33.7	0.78	31.5	35.3	0.82	24.5	29.0	0.68	17.9	30.7	0.96
Benign	25.5	32.7	ref.	29.7	40.7	ref.	21.9	29.1	ref.	18.3	30.8	ref.
Active surveillance	20.5	28.2	0.49	14.1	27.6	0.03b	14.2	22.9	0.20	10.7	18.3	0.15
ThyPRO composite QoL
Malignant	21.5	19.7	0.33	26.7	20.9	0.48	25.5	19.7	0.40	21.1	17.1	0.17
Benign	25.5	15.7	ref.	29.9	19.4	ref.	29.2	20.5	ref.	26.4	18.8	ref.
Active surveillance	20.4	16.0	0.19	18.0	15.6	0.002b	18.7	13.7	0.005b	19.1	14.2	0.05

For the ThyPRO, scores range from 0 (best score) to 100 (worst score).

^aP value indicates the between-group difference for that assessment, using an independent samples t-test and using the benign histopathology group as reference category (ref.); ^bIndicates clinically relevant difference using the MIC values established by Nordqvist et al. (31).